Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial

Torres, V E ; Higashihara, E ; Devuyst, O ; Chapman, A B ; Gansevoort, R T ; Grantham, J J ; Perrone, R D ; Ouyang, J ; Blais, J D ; Czerwiec, F S

American Society of Nephrology 2016

Texto completo disponível